Pyrimidinone-containing 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors
By developing the compound of formula (I) as an inhibitor of 17β-HSD13, the problem of difficult to effectively treat and prevent metabolic diseases such as NAFLD, NASH and HCC in the prior art is solved, and effective inhibition and prevention of these diseases are achieved.
Patent Information
- Application Number
- CN202380036447.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-28
- Filing Date
- 2023-04-26
- Publication Date
- 2024-12-06
AI Technical Summary
The existing 17β-HSD13 inhibitors have not been effective in treating and preventing metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic lipohepatitis (NASH), cirrhosis, hepatocellular carcinoma (HCC).
A compound represented by formula (I) and its pharmaceutical composition are developed as an inhibitor of 17β-HSD13 for the preparation of drugs for the prevention or treatment of the above diseases, and through specific compound structures and synthesis methods, the 17β is achieved. -Effective inhibition of HSD13.
Effectively inhibiting 17β-HSD13 and reducing the risk and symptoms of related diseases, it provides a new treatment and prevention method, especially for metabolic diseases such as NAFLD, NASH and HCC.
Smart Images

Figure CN119095852A_ABST
Abstract
Description
[0001] Related Applications
[0002] This application claims the benefit of U.S. Provisional Application No. 63 / 335,840, filed on April 28, 2022. The entire teachings of the above application are incorporated herein by reference. Technical Field
[0003] The present invention generally relates to compounds and pharmaceutical compositions useful as 17β-HSD13 inhibitors. In particular, the present invention relates to compounds useful as 17β-HSD13 inhibitors and methods of making and using the same. Background Art
[0004] 17-β-Hydroxysteroid dehydrogenase (17β-HSD) is a NADP or NAD+ dependent oxidoreductase that catalyzes the oxidation / reduction reaction of 17β-hydroxysteroids or 17-ketone bodies, respectively. For example, 17β-HSD can catalyze the interconversion of androstenedione and testosterone, estrone and estradiol, or dehydroepiandrosterone (DHEA) and androstenediol. Of the 15 identified 17β-HSDs, except for one (17β-HSD type 5), the rest are short-chain dehydrogenase / reductase (SDR) (JM Day et al., Endocrine-Related Cancer 2008, 15, 665-692).
[0005] More specifically, 17-β-hydroxysteroid dehydrogenase type 13 (17β-HSD13) is encoded by the HSD17B13 gene and is mainly expressed in the liver (S. Liu et al., Acta Biochem. Pol. 2007, 54, 213-218). In addition, 17β-HSD13 was identified as a lipid droplet-associated protein that is upregulated in mice and patients with non-alcoholic fatty liver disease (NAFLD) (Y. Horiguchi et al., Biochem. Biophys. Res. Commun. 2008, 370, 235-238; W. Su et al., Mol. Cell. Endocrinol. 2019, 489, 119-125). Further studies have shown that 17β-HSD13 loss-of-function variants are associated with a significantly reduced risk of NAFLD, cirrhosis associated with nonalcoholic steatohepatitis (NASH), alcoholic liver disease, alcoholic cirrhosis, hepatocellular carcinoma (HCC), NASH disease severity, ballooning degeneration, lobular inflammation, and fibrosis (NSAbul-Husn et al., N. Engl. J. Med. 2018, 378, 1096-1106; CJPirola et al., J. Lipid Res. 1919, 60, 176-185). This variant also shows a reduction in liver damage in obese children (A. Di Sessa et al., J. Pediatr. Gastroenterol. Nutr. 2020, 70, 371-374).
[0006] Small molecule compounds acting as 17β-HSD13 inhibitors have recently been published, WO2023 / 023310, WO 2022 / 020714, WO 2022 / 050730, WO 2021 / 211974, WO 2021 / 003295A1. Other agents acting as 17β-HSD13 inhibitors are disclosed in the following publications: WO 2021 / 211981, WO 2021 / 211959, WO 2020 / 132564, WO2020 / 061177, WO 2019 / 075181, WO 2019 / 183164, WO 2019 / 183629, US2019 / 0106749 and WO2018 / 136758.
[0007] There is a need to develop 17β-HSD13 inhibitors to treat and prevent disease. The present invention has identified compounds that inhibit 17β-HSD13 and methods of using these compounds to treat disease. Summary of the invention
[0008] The present invention relates to compounds and pharmaceutical compositions useful as 17β-HSD13 inhibitors. In particular, the present invention relates to compounds useful as 17β-HSD13 inhibitors and methods of preparing and using the compounds. In addition, the present invention includes methods of preparing the compounds.
[0009] In its main aspect, the present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt or ester thereof:
[0010]
[0011] in,
[0012] M is S, SO, SO 2 , O or NR 7 ;
[0013] R 1 and R 2 Each independently selected from:
[0014] 1) Hydrogen;
[0015] 2) Optionally substituted C 1 -C 8 alkyl;
[0016] 3) Optionally substituted C 2 -C 8 alkenyl;
[0017] 4) Optionally substituted C 2 -C 8 Alkynyl;
[0018] 5) Optionally substituted C 3 -C 8 Cycloalkyl;
[0019] 6) optionally substituted aryl;
[0020] 7) optionally substituted arylalkyl;
[0021] 8) optionally substituted 3 to 8 membered heterocycloalkyl;
[0022] 9) optionally substituted heteroaryl; and
[0023] 10) optionally substituted heteroarylalkyl;
[0024] R 3 , R 4 , R 5 and R 6 are each independently selected from hydrogen, halogen, -CN, -OR 9 、-SR 9 、-C(O)R 7 、-C(O)OR7 、-NR 7 R 8 、-C(O)NR 7 R 8 , optionally substituted C 1 -C 8 alkyl, optionally substituted aryl, and optionally substituted heteroaryl;
[0025] Or, R 5 and R 6 together with the carbon atoms to which they are attached, form an optionally substituted carbocyclic or heterocyclic ring;
[0026] Or, R 4 and R 5 together with the carbon atoms to which they are attached, form an optionally substituted carbocyclic or heterocyclic ring;
[0027] Or, R 3 and R 4 together with the carbon atoms to which they are attached, form an optionally substituted carbocyclic or heterocyclic ring;
[0028] Each R 7 and R 8 Independently selected from:
[0029] 1) Hydrogen;
[0030] 2) Optionally substituted C 1 -C 8 alkyl;
[0031] 3) Optionally substituted C 2 -C 8 alkenyl;
[0032] 4) Optionally substituted C 2 -C 8 Alkynyl;
[0033] 5) Optionally substituted C 3 -C 8 Cycloalkyl;
[0034] 6) optionally substituted 3 to 8 membered heterocycloalkyl;
[0035] 7) optionally substituted aryl;
[0036] 8) optionally substituted arylalkyl;
[0037] 9) optionally substituted heteroaryl; and
[0038] 10) optionally substituted heteroarylalkyl;
[0039] Or, R 7 and R 8together with the nitrogen atom to which they are attached, form an optionally substituted heterocyclic ring;
[0040] R 9 Selected from:
[0041] 1) Hydrogen;
[0042] 2) Optionally substituted C 1 -C 8 alkyl;
[0043] 3) Optionally substituted C 2 -C 8 alkenyl;
[0044] 4) Optionally substituted C 2 -C 8 Alkynyl;
[0045] 5) Optionally substituted C 3 -C 8 Cycloalkyl;
[0046] 6) optionally substituted 3 to 8 membered heterocycloalkyl;
[0047] 7) optionally substituted aryl;
[0048] 8) optionally substituted arylalkyl;
[0049] 9) optionally substituted heteroaryl;
[0050] 10) optionally substituted heteroarylalkyl;
[0051] 11)-C(O)R 11 ;
[0052] 12)-C(O)NR 11 R 12 ;
[0053] 13)-C(O)OR 11 ;
[0054] 14)-P(O)(OR 13 ) 2 ;as well as
[0055] 15)-P(O)(OR 13 )(NR 11 R 12 );
[0056] Each R 11 and R 12 Independently selected from:
[0057] 1) Hydrogen;
[0058] 2) Optionally substituted C 1-C 8 alkyl;
[0059] 3) Optionally substituted C 2 -C 8 alkenyl;
[0060] 4) Optionally substituted C 2 -C 8 Alkynyl;
[0061] 5) Optionally substituted C 3 -C 8 Cycloalkyl;
[0062] 6) optionally substituted 3 to 8 membered heterocycloalkyl;
[0063] 7) optionally substituted aryl;
[0064] 8) optionally substituted arylalkyl;
[0065] 9) optionally substituted heteroaryl; and
[0066] 10) optionally substituted heteroarylalkyl;
[0067] And R 13 is hydrogen, optionally substituted C 1 -C 8 Alkyl or Na+.
[0068] In certain embodiments, the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound or compound combination of the present invention, or a pharmaceutically acceptable salt, ester or combination thereof, and a pharmaceutically acceptable carrier or excipient.
[0069] In certain embodiments, the present invention provides a method for preventing or treating a disease or condition mediated by 17β-HSD13. The method comprises administering an effective therapeutic amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. The present invention also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a medicament for preventing or treating a disease or condition mediated by 17β-HSD13, the disease or condition including but not limited to: non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), cirrhosis, liver fibrosis, hepatocellular carcinoma (HCC) and other metabolic diseases. DETAILED DESCRIPTION
[0070] In one embodiment of the present invention, it is a compound represented by formula (I) as described above or a pharmaceutically acceptable salt or ester thereof.
[0071] In certain embodiments of the compound of Formula (I), R 3 is hydrogen or a halogen.
[0072] In certain embodiments of the compound of Formula (I), R 4 is hydrogen or a halogen.
[0073] In certain embodiments of the compound of Formula (I), R 5 is hydrogen or a halogen.
[0074] In certain embodiments of the compound of Formula (I), R 3 is hydrogen, R 4 is hydrogen, R 5 It's hydrogen.
[0075] In certain embodiments of the compound of Formula (I), R 6 Yes-OR 9 .
[0076] In certain embodiments of the compound of Formula (I), R 6 It is -OH.
[0077] In certain embodiments of the compound of Formula (I), R 1 is optionally substituted aryl or optionally substituted heteroaryl.
[0078] In certain embodiments of the compound of Formula (I), R 1 is an optionally substituted heterocycloalkyl-C 1 -C 6 alkyl.
[0079] In certain embodiments of the compound of Formula (I), R 1 is an optionally substituted C 3 -C 8 Cycloalkyl or optionally substituted 3- to 8-membered heterocycloalkyl.
[0080] In certain embodiments of the compound of Formula (I), R 1 is selected from the following groups, each of which is optionally substituted:
[0081]
[0082] In certain embodiments of the compound of Formula (I), R 2 is an optionally substituted C 1 -C 8 Alkyl, preferably optionally substituted C 1 -C 6 Preferred substituents include halogen, C 3 -C 6 Cycloalkyl, hydroxyl, amino, C 1 -C 6 Alkylamino, di(C 1 -C 6 Alkyl)amino, C1 -C 6 Alkane NHC(O)-, di(C 1 -C 6 -alkyl)NC(O) and -C(O)OC 1 -C 6 alkyl.
[0083] In certain embodiments of the compound of Formula (I), R 2 is an optionally substituted C 2 -C 8 Alkenyl, preferably optionally substituted C 2 -C 6 Preferred substituents include halogen, C 3 -C 6 Cycloalkyl, hydroxyl, amino, C 1 -C 6 Alkylamino, di(C 1 -C 6 alkyl)amino and -C(O)OC 1 -C 6 alkyl.
[0084] In certain embodiments of the compound of Formula (I), R 2 is an optionally substituted C 3 -C 8 Cycloalkyl, preferably optionally substituted C 3 -C 6 -cycloalkyl. Preferred substituents include halogen, C 1 -C 4 Alkyl and hydroxyl.
[0085] In certain embodiments of the compound of Formula (I), R 2 is optionally substituted aralkyl or optionally substituted heteroaralkyl.
[0086] In certain embodiments of the compound of Formula (I), R 2 is an optionally substituted aryl-C 1 -C 6 alkyl, optionally substituted heteroaryl-C 1 -CH2-alkyl or optionally substituted heterocyclyl-C 1 -C 6 -alkyl, preferably optionally substituted aryl-C 1 -C 4 -alkyl, optionally substituted heteroaryl-C 1 -C 4 Alkyl or optionally substituted heterocyclyl-C 1 -C 4 Preferred substituents include halogen, C 1 -C 4Alkyl and hydroxyl.
[0087] In certain embodiments of the compound of Formula (I), R 2 is an optionally substituted aryl-C 2 -C 6 -alkenyl, optionally substituted heteroaryl-C 2 -C 6 -alkenyl or optionally substituted heterocyclyl-C 2 -C 6 -alkenyl, preferably optionally substituted aryl-C 2 -C 4 -alkenyl, optionally substituted heteroaryl-C 2 -C 4 alkenyl or optionally substituted heterocyclyl-C 2 -C 4 -alkenyl. Preferred substituents include halogen, C 1 -C 4 Alkyl and hydroxyl.
[0088] In certain embodiments of the compound of Formula (I), R 2 is optionally substituted -C 1 -C 4 -alkylN(R)-C 1 -C 4 -alkylaryl, optionally substituted-C 1 -C 4 -alkylN(R)-C 1 -C 4 Alkyl heterocyclic group, where R is H or C 1 -C 4 -alkyl. Preferred substituents include halogen, C 1 -C 4 Alkyl and hydroxyl.
[0089] In certain embodiments of the compound of Formula (I), R 2 Yes-C 1 -C 6 -alkyl-L-R', wherein L is -O-, -S-, -N(R)-, -N(R)C(O)-, -NRC(O)O-, or N(R)SO 2 -; R' is an optionally substituted C 1 -C 6 alkyl, optionally substituted aryl or optionally substituted heteroaryl; or R, R' and the nitrogen atom to which they are attached form an optionally substituted 3- to 8-membered heterocyclic group.
[0090] In certain embodiments of the compound of Formula (I), R 2 Selected from the following, each of which is optionally substituted:
[0091]
[0092]
[0093] In one embodiment, the present invention provides a compound represented by formula (II) or (III), or a pharmaceutically acceptable salt or ester thereof:
[0094]
[0095] Among them, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 As mentioned before.
[0096] In certain embodiments, the present invention provides a compound represented by formula (IV) or (V), or a pharmaceutically acceptable salt or ester thereof:
[0097]
[0098] Among them, R 1 , R 2 , R 3 , R 4 , R 5 , R 7 and R 9 As mentioned before.
[0099] In certain embodiments, the present invention provides a compound represented by formula (IV) or (V), or a pharmaceutically acceptable salt or ester thereof, wherein R 9 is selected from the following groups, each of which is optionally substituted:
[0100]
[0101] In one embodiment, the present invention provides a compound represented by formula (VI) or (VII), or a pharmaceutically acceptable salt or ester thereof:
[0102]
[0103] Among them, R 1 , R 2 , R 3 , R 6 and R 7 As mentioned before.
[0104] In certain embodiments, the present invention provides a compound represented by formula (VIII) or (IX), or a pharmaceutically acceptable salt or ester thereof:
[0105]
[0106] Among them, R 1 , R 2 , R 3 , R 7 and R 9 As mentioned before.
[0107] In certain embodiments, the present invention provides a compound represented by formula (X) or (XI), or a pharmaceutically acceptable salt or ester thereof:
[0108]
[0109] Among them, R 1 , R 2 , R 7 and R 9 As mentioned above. Preferably R 9 It's hydrogen.
[0110] In certain embodiments, the present invention provides a compound represented by formula (X) or (XI), or a pharmaceutically acceptable salt or ester thereof, wherein R 9 Selected from the following, each of which is optionally substituted:
[0111]
[0112] Representative compounds of the present invention include, but are not limited to, the following compounds according to formula (X) (entries 1 to 80 in Table 1), wherein R 9 is hydrogen, and R of each compound in Table 1 1 and R 2 All are listed.
[0113] Table 1
[0114]
[0115]
[0116]
[0117]
[0118]
[0119]
[0120] Representative compounds of the present invention include, but are not limited to, the following compounds according to formula (X) (entries 81 to 230 in Table 2), wherein R of each compound in Table 2 is 1, R 2 and R 9 They are all listed.
[0121] Table 2
[0122]
[0123]
[0124]
[0125]
[0126]
[0127]
[0128]
[0129]
[0130]
[0131]
[0132]
[0133]
[0134]
[0135]
[0136]
[0137]
[0138]
[0139] In certain embodiments, the present invention provides a compound represented by formula (XII) or (XIII), or a pharmaceutically acceptable salt or ester thereof:
[0140]
[0141] Each R 21 , R 22 , R 23 , R 24 or R 25 are independently hydrogen, halogen, optionally substituted C 1 -C 6 Alkyl, optionally substituted C1 -C 6 Alkoxy or optionally substituted C 3 -C 8 Cycloalkyl; R 26 is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted C 3 -C 8 Cycloalkyl, optionally substituted C 1 -C 6 Alkyl, -NR 7 R 8 、-CH 2 NR 7 R 8 and -CH 2 NR 7 C(O)R 8 ,or R 3 , R 7 , R 8 and R 9 As mentioned before.
[0142] Or, R 21 and R 22 Together with the carbon atom to which they are attached they form an optionally substituted carbocyclic or heterocyclic ring fused to the phenyl group.
[0143] Or, R 22 and R 23 Together with the carbon atom to which they are attached they form an optionally substituted carbocyclic or heterocyclic ring fused to the phenyl group.
[0144] Or, R 7 and R 8 Together with the nitrogen atom to which they are attached they form an optionally substituted heterocyclic ring.
[0145] In certain embodiments, the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound or compound combination of the present invention, or a pharmaceutically acceptable salt, ester or combination thereof, and a pharmaceutically acceptable carrier or excipient.
[0146] In certain embodiments, the present invention provides a method for preventing or treating a disease or condition mediated by 17β-HSD13. The method comprises administering an effective therapeutic amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. The present invention also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a medicament for preventing or treating a disease or condition mediated by 17β-HSD13, the disease or condition including but not limited to: non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), cirrhosis, liver fibrosis, hepatocellular carcinoma (HCC) and metabolic diseases.
[0147] It should be understood that the present invention is described herein in accordance with the laws and principles of chemical bonding. In some cases, it may be necessary to remove hydrogen atoms in order to accommodate a substituent at any given position.
[0148] It should be understood that the compounds of the present invention can contain one or more asymmetric carbon atoms and can exist in racemic, diastereoisomer and optically active forms. It should still be understood that some compounds of the present invention can exist in different tautomeric forms. All tautomers are expected to be within the scope of the present invention.
[0149] It is to be understood that the compounds encompassed by the present invention are those stable compounds suitable for use as pharmaceutical formulations.
[0150] definition
[0151] Listed below are definitions of various terms used to describe the present invention. These definitions apply to the terms as used in this specification and claims, unless otherwise limited in specific instances, whether used individually or as part of a larger group.
[0152] The term "aryl" as used herein refers to a monocyclic or polycyclic carbon ring system containing at least one aromatic ring. Preferred aryl groups are C 6 -C 12 Aryl, including but not limited to phenyl, naphthyl, tetrahydronaphthyl, dihydroindenyl and indenyl. Polycyclic aromatic groups are polycyclic ring systems containing at least one aromatic ring. Polycyclic aromatic groups may include fused rings, covalently linked rings or combinations thereof.
[0153] The term "heteroaryl" as used herein refers to a monocyclic or polycyclic aromatic group having one or more ring atoms selected from S, O and N; and the remaining ring atoms are carbon, wherein any N or S contained in the ring can be optionally oxidized. In certain embodiments, heteroaryl is a 5 to 10 yuan heteroaryl, such as a 5 or 6 yuan monocyclic heteroaryl or an 8 to 10 yuan bicyclic heteroaryl. Heteroaryl includes but is not limited to pyridyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, thiadiazolyl, oxadiazolyl, thienyl, furanyl, quinolyl, isoquinolyl, benzimidazolyl, benzoxazolyl, quinoxalinyl. Polycyclic heteroaryl can include fused rings, covalently linked rings or combinations thereof. Where possible, heteroaryl can be C-connected or N-connected.
[0154] According to the present invention, aryl and heteroaryl groups may be substituted or unsubstituted.
[0155] The term "bicyclic aryl" or "bicyclic heteroaryl" refers to a ring system consisting of two rings, at least one of which is aromatic; and the two rings may be fused or covalently linked.
[0156] The term "alkyl" as used herein refers to a saturated straight or branched chain hydrocarbon group. 1 -C 4 Alkyl", "C 1 -C 6 Alkyl", "C 1 -C 8 Alkyl", "C 1 -C 12 Alkyl", "C 2 -C 4 Alkyl" and "C 3 -C 6 The term "alkyl" refers to an alkyl group containing 1 to 4, 1 to 6, 1 to 8, 1 to 12, 2 to 4, and 3 to 6 carbon atoms, respectively. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, n-pentyl, neopentyl, n-hexyl, n-heptyl, and n-octyl.
[0157] As used herein, the term "alkenyl" refers to a straight or branched chain hydrocarbon group having at least one carbon-carbon double bond. 2 -C 8 Alkenyl", "C 2 -C 12 Alkenyl", "C 2 -C 4 Alkenyl", "C 3 -C 4 "Alkenyl" and "C 3 -C 6 The term "alkenyl" refers to an alkenyl group containing 2 to 8, 2 to 12, 2 to 4, 3 to 4 or 3 to 6 carbon atoms, respectively. Alkenyl includes, but is not limited to, ethenyl, propenyl, butenyl, 2-methyl-2-buten-2-yl, heptenyl, octenyl and the like.
[0158] As used herein, the term "alkynyl" refers to a straight or branched chain hydrocarbon group having at least one carbon-carbon triple bond. 2 -C 8 Alkynyl", "C 2 -C 12 Alkynyl", "C 2 -C 4 Alkynyl", "C 3 -C 4 Alkynyl" and "C 3 -C 6 "Alkynyl" refers to alkynyl groups containing 2 to 8, 2 to 12, 2 to 4, 3 to 4 or 3 to 6 carbon atoms, respectively. Representative alkynyl groups include, but are not limited to, ethynyl, 2-propynyl, 2-butynyl, heptynyl, octynyl and the like.
[0159] The term "cycloalkyl" as used herein refers to a monocyclic or polycyclic saturated carbocyclic ring, such as a bicyclic or tricyclic fused, bridged or spirocyclic ring system. The ring carbon atoms are optionally substituted by oxo or optionally substituted by an exocyclic olefin double bond. Preferred cycloalkyl groups include C 3 -C 12 Cycloalkyl, C 3 -C 6 Cycloalkyl, C 3 -C 8 Cycloalkyl and C 4 -C 7 Cycloalkyl. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentyl, cyclooctyl, 4-methylenecyclohexyl, bicyclo[2.2.1]heptyl, bicyclo[3.1.0]hexyl, spiro[2.5]octyl, 3-methylenebicyclo[3.2.1]octyl, spiro[4.4]nonyl, and the like.
[0160] The term "cycloalkenyl" as used herein refers to a monocyclic or polycyclic carbocyclic ring, such as a bicyclic or tricyclic fused, bridged or spirocyclic ring system having at least one carbon-carbon double bond. The ring carbon atoms are optionally substituted by oxo or optionally substituted by an exocyclic olefin double bond. Preferred cycloalkenyl groups include C 3 -C 12 Cycloalkenyl, C 4 -C 12 Cycloalkenyl, C 3 -C 8 Cycloalkenyl, C 4 -C 8 Cycloalkenyl and C 5 -C 7 Cycloalkenyl. Examples of cycloalkenyl groups include, but are not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cyclooctenyl, bicyclo[2.2.1]hept-2-enyl, bicyclo[3.1.0]hex-2-enyl, spiro[2.5]oct-4-enyl, spiro[4.4]non-2-enyl, and bicyclo[4.2.1]non-3-en-12-yl, and the like.
[0161] As used herein, the term "aralkyl" refers to a functional group in which an alkylene chain is attached to an aryl group, for example -(CH 2 )n-phenyl, wherein n is 1 to 12, preferably 1 to 6, more preferably 1 or 2. The term "substituted aralkyl" refers to an arylalkyl functional group in which the aryl group is substituted. Similarly, the term "heteroaralkyl" refers to a functional group in which an alkylene chain is attached to a heteroaryl group, for example -(CH 2 )n-heteroaryl, wherein n is 1 to 12, preferably 1 to 6, more preferably 1 or 2. The term "substituted heteroarylalkyl" refers to a heteroarylalkyl functional group in which a heteroaryl group is substituted.
[0162] As used herein, the term "alkoxy" refers to a group in which an alkyl group having the specified number of carbon atoms is attached to the remainder of the molecule through an oxygen atom. Alkoxy includes C 1 -C 12 Alkoxy, C 1 -C 8 Alkoxy, C 1 -C 6 Alkoxy, C 1 -C 4 Alkoxy and C 1 -C 3 Alkoxy. Examples of alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, 2-propoxy (isopropoxy) and higher homologs and isomers. Preferred alkoxy is C 1 -C 3 Alkoxy.
[0163] An "aliphatic" group is a non-aromatic moiety composed of any combination of carbon atoms, hydrogen atoms, halogen atoms, oxygen, nitrogen or other atoms, and optionally contains one or more unsaturated units, such as double bonds and / or triple bonds. Examples of aliphatic groups are functional groups such as alkyl, alkenyl, alkynyl, O, OH, NH, NH 2 、C(O)、S(O) 2 ,C(O)O,C(O)NH,OC(O)O,OC(O)NH,OC(O)NH 2 、S(O) 2 NH, S(O) 2 NH 2 、NHC(O)NH 2 、NHC(O)C(O)NH、NHS(O) 2 NH, NHS(O) 2 NH 2 、C(O)NHS(O) 2 、C(O)NHS(O) 2 NH or C(O)NHS(O) 2 NH 2 The like, groups containing one or more functional groups, non-aromatic hydrocarbons (optionally substituted) and groups in which one or more carbons of non-aromatic hydrocarbons (optionally substituted) are replaced by functional groups. The carbon atoms of the aliphatic group may be optionally substituted by oxo. The aliphatic group may be linear, branched, cyclic or a combination thereof, preferably containing from about 1 to about 24 carbon atoms, more typically containing from about 1 to about 12 carbon atoms. In addition to the aliphatic hydrocarbon groups used herein, aliphatic groups explicitly include, for example, alkoxyalkyl, polyalkoxyalkyl, such as polyalkylene glycols, polyamines and polyimines. The aliphatic group may be optionally substituted.
[0164] The terms "heterocycle" and "heterocycloalkyl" are used interchangeably and refer to a non-aromatic ring or polycyclic ring system, such as a bicyclic or tricyclic fused, bridged or spiro ring system, wherein (i) each ring system contains at least one heteroatom independently selected from oxygen, sulfur and nitrogen, (ii) each ring system may be saturated or unsaturated, (iii) the nitrogen and sulfur heteroatoms may be optionally oxidized, (iv) the nitrogen heteroatom may be optionally quaternized, (v) any of the above rings may be fused to an aromatic ring, and (vi) the remaining ring atoms are carbon atoms which may be optionally oxo-substituted or optionally substituted with an exocyclic olefinic double bond. Representative heterocycloalkyl includes but is not limited to 1,3-dioxolane, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, quinoxalinyl, pyridazinonyl, 2-azabicyclo [2.2.1] -heptyl, 8-azabicyclo [3.2.1] octyl, 5-azaspiro [2.5] octyl, 2-oxa-7-azaspiro [4.4] nonyl, 7-oxoxacycloheptan-4-yl and tetrahydrofuranyl. This heterocycle or heterocycloalkyl can be further substituted. Where possible, heterocycloalkyl or heterocyclic group can be C- connected or N- connected.
[0165] It should be understood that any alkyl, alkenyl, alkynyl, alicyclic, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocycle, aliphatic moiety, etc. described herein can also be a divalent or multivalent group when used as a link to connect two or more groups or substituents, which can be on the same or different atoms. Those skilled in the art can easily determine the valence of any such group based on the context in which it appears.
[0166] The term "substituted" refers to the replacement of one, two, three or more hydrogen atoms with the following substituents independently, including but not limited to: -F, -Cl, -Br, -I, -OH, C 1 -C 12 Alkyl; C 2 -C 12 Alkenyl, C 2 -C 12 Alkynyl, -C 3 -C 12 Cycloalkyl, protected hydroxyl, -NO 2 、-N3、-CN、-NH 2 , protected amino, oxo, thio, -NH-C 1 -C 12 Alkyl, -NH-C 2 -C 8 Alkenyl, -NH-C 2 -C 8 Alkynyl, -NH-C 3 -C 12Cycloalkyl, -NH-aryl, -NH-heteroaryl, -NH-heterocycloalkyl, dialkylamino, diarylamino, diheteroarylamino, -OC 1 -C 12 Alkyl, -OC 2 -C 8 Alkenyl, -OC 2 -C 8 Alkynyl, -OC 3 -C 12 Cycloalkyl, -O-aryl, -O-heteroaryl, -O-heterocycloalkyl, -C(O)-C 1 -C 12 Alkyl, -C(O)-C 2 -C 8 Alkenyl, -C(O)-C 2 -C 8 Alkynyl, -C(O)-C 3 -C 12 Cycloalkyl, -C(O)-aryl, -C(O)-heteroaryl, -C(O)-heterocycloalkyl, -CONH 2 、-CONH-C 1 -C 12 Alkyl, -CONH-C 2 -C 8 Alkenyl, -CONH-C 2 -C 8 Alkynyl, -CONH-C 3 -C 12 Cycloalkyl, -CONH-aryl, -CONH-heteroaryl, -CONH-heterocycloalkyl, -OCO 2 -C 1 -C 12 Alkyl, -OCO 2 -C 2 -C 8 Alkenyl, -OCO 2 -C 2 -C 8 Alkynyl, -OCO 2 -C 3 -C 12 Cycloalkyl, -OCO 2 -Aryl, -OCO 2 -heteroaryl, -OCO 2 -heterocycloalkyl, -CO 2 -C 1 -C 12 Alkyl, -CO 2 -C 2 -C 8 Alkenyl, -CO 2 -C 2 -C8 Alkynyl, -CO 2 -C 3 -C 12 Cycloalkyl, -CO 2 -Aryl, -CO 2 -heteroaryl, -CO 2 -heterocycloalkyl, -OCONH 2 、-OCONH-C 1 -C 12 Alkyl, -OCONH-C 2 -C 8 Alkenyl, -OCONH-C 2 -C 8 Alkynyl, -OCONH-C 3 -C 12 Cycloalkyl, -OCONH-aryl, -OCONH-heteroaryl, -OCONH-heterocycloalkyl, -NHC(O)H, -NHC(O)-C 1 -C 12 Alkyl, -NHC(O)-C 2 -C 8 Alkenyl, -NHC(O)-C 2 -C 8 Alkynyl, -NHC(O)-C 3 -C 12 Cycloalkyl, -NHC(O)-aryl, -NHC(O)-heteroaryl, -NHC(O)-heterocycloalkyl, -NHC(O) 2 -C 1 -C 12 Alkyl, -NHCO 2 -C 2 -C 8 Alkenyl, -NHCO 2 -C 2 -C 8 Alkynyl, -NHCO 2 -C 3 -C 12 Cycloalkyl, -NHCO 2 -Aryl, -NHCO 2 -heteroaryl, -NHCO 2 -heterocycloalkyl, -NHC(O)NH 2 、-NHC(O)NH-C 1 -C 12 Alkyl, -NHC(O)NH-C 2 -C 8 Alkenyl, -NHC(O)NH-C 2 -C 8 Alkynyl, -NHC(O)NH-C 3 -C12 Cycloalkyl, -NHC(O)NH-aryl, -NHC(O)NH-heteroaryl, -NHC(O)NH-heterocycloalkyl, -NHC(S)NH 2 、-NHC(S)NH-C 1 -C 12 Alkyl, -NHC(S)NH-C 2 -C 8 Alkenyl, -NHC(S)NH-C 2 -C 8 Alkynyl, -NHC(S)NH-C 3 -C 12 Cycloalkyl, -NHC(S)NH-aryl, -NHC(S)NH-heteroaryl, -NHC(S)NH-heterocycloalkyl, -NHC(NH)NH 2 、-NHC(NH)NH-C 1 -C 12 Alkyl, -NHC(NH)NH-C 2 -C 8 Alkenyl, -NHC(NH)NH-C 2 -C 8 Alkynyl, -NHC(NH)NH-C 3 -C 12 Cycloalkyl, -NHC(NH)NH-aryl, -NHC(NH)NH-heteroaryl, -NHC(NH)NH-heterocycloalkyl, -NHC(NH)-C 1 -C 12 Alkyl, -NHC(NH)-C 2 -C 8 Alkenyl, -NHC(NH)-C 2 -C 8 Alkynyl, -NHC(NH)-C 3 -C 12 Cycloalkyl, -NHC(NH)-aryl, -NHC(NH)-heteroaryl, -NHC(NH)-heterocycloalkyl, -C(NH)NH 2 、-C(NH)NH-C 1 -C 12 Alkyl, -C(NH)NH-C 2 -C 8 Alkenyl, -C(NH)NH-C 2 -C 8 Alkynyl, -C(NH)NH-C 3 -C 12 Cycloalkyl, -C(NH)NH-aryl, -C(NH)NH-heteroaryl, -C(NH)NH-heterocycloalkyl, -S(O)-C 1 -C 12Alkyl, -S(O)-C 2 -C 8 Alkenyl, -S(O)-C 2 -C 8 Alkynyl, -S(O)-C 3 -C 12 Cycloalkyl, -S(O)-aryl, -S(O)-heteroaryl, -S(O)-heterocycloalkyl, -SO 2 NH 2 、-SO 2 NH-C 1 -C 12 Alkyl, -SO 2 NH-C 2 -C 8 Alkenyl, -SO 2 NH-C 2 -C 8 Alkynyl, -SO 2 -C 1 -C 12 Alkyl, -SO 2 -C 2 -C 8 Alkenyl, -SO 2 -C 2 -C 8 Alkynyl, -SO 2 -C 3 -C 12 Cycloalkyl, -SO 2 -Aryl, -SO 2 -heteroaryl, -SO 2 -heterocycloalkyl, -SO 2 NH-C 3 -C 12 Cycloalkyl, -SO 2 NH-aryl, -SO 2 NH-heteroaryl, -SO 2 NH-heterocycloalkyl, -NHSO 2 -C 1 -C 12 Alkyl, -NHSO 2 -C 2 -C 8 Alkenyl, -NHSO 2 -C 2 -C 8 Alkynyl, -NHSO 2 -C 3 -C 12 Cycloalkyl, -NHSO 2 -Aryl, -NHSO 2 -heteroaryl, -NHSO 2 -heterocycloalkyl, -CH2 NH 2 、-CH 2 SO 2 CH 3 , -aryl, -arylalkyl, -heteroaryl, -heteroarylalkyl, -heterocycloalkyl, -C 3 -C 12 Cycloalkyl, polyalkoxyalkyl, polyalkoxy, -methoxymethoxy, -methoxyethoxy, -SH, -SC 1 -C 12 Alkyl, -SC 2 -C 8 Alkenyl, -SC 2 -C 8 Alkynyl, -SC 3 -C 12 In certain embodiments, the substituents are independently selected from halogen, preferably Cl and F; C 1 -C 4 Alkyl, preferably methyl and ethyl; halogenated C 1 -C 4 Alkyl, such as fluoromethyl, difluoromethyl and trifluoromethyl; C 2 -C 4 Alkenyl; Halogenated C 2 -C 4 Alkenyl; C 3 -C 6 Cycloalkyl, such as cyclopropyl; C 1 -C 4 Alkoxy, such as methoxy and ethoxy; halogenated C 1 -C 4 Alkoxy, such as fluoromethoxy, difluoromethoxy, and trifluoromethoxy; -CN; -OH; NH 2 ; C 1 -C 4 Alkylamino; di(C 1 -C 4 alkyl)amino group; and NO 2 It should be understood that the aryl, heteroaryl, alkyl, alkenyl, alkynyl, cycloalkyl or heterocycloalkyl in the substituent may be further substituted. In certain embodiments, the substituent in the substituted moiety is further optionally substituted with one or more groups, each group independently selected from C 1 -C 4 Alkyl; -CF 3 、-OCH 3 、-OCF 3 , -F, -Cl, -Br, -I, -OH, -NO 2 , -CN and -NH 2Preferably, the substituted alkyl group is substituted by one or more halogen atoms, more preferably by one or more fluorine or chlorine atoms.
[0167]
[0046] The terms "halo" or "halogen" as used herein, alone or as part of another substituent, refer to a fluorine, chlorine, bromine or iodine atom.
[0168] As used herein, the term "optionally substituted" means that the referenced group may be substituted or unsubstituted. In one embodiment, the referenced group is optionally substituted with zero substituents, i.e., the referenced group is unsubstituted. In certain embodiments, the referenced group is optionally substituted with one or more additional groups individually and independently selected from the groups described herein.
[0169] The term "hydrogen" includes hydrogen and deuterium. In addition, the expression of an element includes all isotopes of the element, as long as the resulting compound is pharmaceutically acceptable. In certain embodiments, the isotope of the element is present in a specific position according to its natural abundance. In other embodiments, one or more isotopes of the element at a specific position are enriched to exceed its natural abundance.
[0170] The term "hydroxyl activating group" as used herein refers to an unstable chemical moiety known in the art that activates a hydroxyl group, allowing it to be separated during a synthetic process such as a substitution or elimination reaction. Examples of hydroxyl activating groups include, but are not limited to, methanesulfonates, toluenesulfonates, trifluoromethanesulfonates, p-nitrobenzoates, phosphonates, and the like.
[0171] As used herein, the term "activated hydroxyl" refers to a hydroxyl group activated with a hydroxyl activating group, as described above, including but not limited to mesylate, tosylate, triflate, p-nitrobenzoate, phosphonate groups.
[0172] As used herein, the term "hydroxy protecting group" refers to a labile chemical moiety known in the art that is used to protect a hydroxy group from undesirable reactions during a synthetic process. After the synthetic steps described, the hydroxy protecting group described herein can be selectively removed. Hydroxyl protecting groups known in the art are generally described in PGM Wuts, Greene's Protective Groups in Organic Synthesis, 5th edition, John Wiley & Sons, Hoboken, NJ (2014). Examples of hydroxyl protecting groups include, but are not limited to, benzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, tert-butyloxycarbonyl, isopropyloxycarbonyl, diphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, allyloxycarbonyl, acetyl, formyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetylbenzoyl, methyl, tert-butyl, 2,2,2 trichloroethyl, 2-trimethylsilylethyl, allyl, benzyl, triphenylmethyl (trityl), methoxymethyl, methylthiomethyl, benzyloxymethyl, 2-(trimethylsilyl)-ethoxymethyl, methylsulfonyl, trimethylsilyl, triisopropylsilyl, and the like.
[0173] The term "protected hydroxy" as used herein refers to a hydroxy group protected with a hydroxy protecting group as described above, including but not limited to benzoyl, acetyl, trimethylsilyl, triethylsilyl and methoxymethyl.
[0174] The term "hydroxy prodrug group" as used herein refers to an initial group known in the art that changes the physicochemical properties of the parent drug in a transient manner by covering or masking the hydroxyl group, thereby changing its biological properties. After the synthetic procedure, the hydroxy prodrug group described herein must be able to revert to the hydroxyl group in vivo. Hydroxyl prodrug groups known in the art are generally described in Kenneth B. Sloan, Proddrugs, TopicalandOcularDrugDelivery , (Drugs and the Pharmaceutical Sciences; Volume 53), Marcel Dekker, Inc., New York (1992).
[0175] As used herein, the term "amino protecting group" refers to a labile chemical moiety known in the art that is used to protect an amino group from undesired reactions during a synthetic process. After the synthetic process, the amino protecting group described herein can be selectively removed. Amino protecting groups known in the art are generally described in PGM Wuts, Greene's Protective Groups in Organic Synthesis , 5th edition, John Wiley & Sons, Hoboken, NJ (2014). Examples of amino protecting groups include, but are not limited to, methoxycarbonyl, tert-butyloxycarbonyl, 12-fluorenylmethoxycarbonyl, benzyloxycarbonyl, and the like.
[0176] The term "protected amino group" as used herein refers to an amino group protected with an amino protecting group as described above.
[0177] The term "leaving group" refers to a functional group or atom that can be replaced by another functional group or atom in a substitution reaction (such as a nucleophilic substitution reaction). For example, representative leaving groups include chloro, bromo and iodo groups; sulfonate groups, such as mesylate, tosylate, benzenesulfonate, mesylate, etc.; and acyloxy groups, such as acetoxy, trifluoroacetoxy, etc.
[0178] As used herein, the term "aprotic solvent" refers to a solvent that is relatively inert to proton activity, i.e., does not act as a proton donor. Examples include, but are not limited to, hydrocarbons such as hexane and toluene, halogenated hydrocarbons such as dichloromethane, vinyl chloride, chloroform, etc., heterocyclic compounds such as tetrahydrofuran and N-methylpyrrolidone, and ethers such as diethyl ether and bismethoxymethyl ether. These compounds are well known to those skilled in the art, and it will be apparent to those skilled in the art that a single solvent or a mixture thereof may be preferred for a particular compound and reaction conditions, depending on factors such as the solubility of the reagents, the reactivity of the reagents, and the preferred temperature range. Further discussion of aprotic solvents can be found in organic chemistry textbooks or professional monographs, for example: Organic Solvents Physical Properties andMethods ofPurification , 4th edition, John A. Riddick et al., eds., Volume II, in Techniques of Chemistry Series , John Wiley & Sons, NY, 1986.
[0179] As used herein, the term "protic solvent" refers to a solvent that tends to donate a proton, for example, an alcohol, such as methanol, ethanol, propanol, isopropanol, butanol, tert-butanol, etc. Such solvents are well known to those skilled in the art, and it is obvious to those skilled in the art that, for a particular compound and reaction conditions, a single solvent or a mixture thereof may be preferred, depending on factors such as the solubility of the reagents, the reactivity of the reagents, and the preferred temperature range. Further discussion of proton-donating solvents can be found in organic chemistry textbooks or specialized monographs, for example: OrganicSolventsPhy sicalPropertiesandMethodsofPurification , 4th edition, edited by John A.Riddick et al., Volume II, Techniques of Chemistry Series ,John Wiley & Sons,NY,1986.
[0180] The combinations of substituents and variables contemplated by this invention are only those that result in the formation of stable compounds. As used herein, the term "stable" refers to compounds that have stability sufficient to allow manufacturing and maintain the integrity of the compound for a sufficient period of time to be useful for the purposes detailed herein (e.g., for therapeutic or prophylactic administration to a subject).
[0181] The synthesized compound can be isolated from the reaction mixture and further purified by methods such as column chromatography, high pressure liquid chromatography or recrystallization. As will be appreciated by those skilled in the art, other methods for synthesizing the compounds of the formula herein will be apparent to those of ordinary skill in the art. In addition, the various synthetic steps can be performed in an alternating sequence or order to obtain the desired compound. Synthetic chemical transformations and protecting group methods (protection and deprotection) for synthesizing the compounds described herein are known in the art and include, for example, R. Larock, ComprehensiveOrg anicTransformations , 2nd edition. Wiley-VCH (1999); PGMWuts, Greene's Protective Groups in Organic Synthesis , 5th edition, John Wiley & Sons, Hoboken, NJ (2014); L. Fieser and M. Fieser, FieserandFieser'sReagentsforOrganicSynthesis ,John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia ofReagents forOrganic Synthesis , John Wiley and Sons (1995), and subsequent editions.
[0182] The term "subject" as used herein refers to an animal. Preferably, the animal is a mammal. More preferably, the mammal is a human. For example, the subject also refers to a dog, a cat, a horse, a cow, a pig, a guinea pig, a fish, a bird, etc.
[0183] The compounds of the present invention can be modified by adding appropriate functional groups to enhance selective biological properties. Such modifications are known in the art and may include those that increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolic rate, and alter excretion rate.
[0184] The compounds described herein contain one or more asymmetric centers and thus give rise to enantiomers, diastereomers, and other stereoisomeric forms which, in terms of absolute stereochemistry, can be defined as (R)- or (S)-, or (D) / or (L)- of an amino acid. The present invention is intended to include all such possible isomers, as well as their racemic and optically pure forms. Optical isomers can be prepared by the above procedures or by resolving the racemic mixtures from their respective optically active precursors. The resolution can be carried out in the presence of a resolving agent, by chromatography or repeated crystallization, or by some combination of these techniques known to those skilled in the art. Further details on the resolution can be found in Jacques et al. Enantiomers,Racemates,andResolutions(John Wiley & Sons, 1981). When the compounds described herein contain olefinic double bonds, other unsaturation, or other centers of geometric asymmetry, unless otherwise specified, the compounds shall include E and Z geometric isomers or cis and trans isomers. Likewise, all tautomeric forms shall also be included. Tautomers may be cyclic or acyclic. The configuration of any carbon-carbon double bond appearing herein is selected for convenience only and is not intended to specify a particular configuration unless otherwise specified in the text; therefore, any carbon-carbon double bond or carbon heteroatom double bond described herein as trans may be cis, trans, or a mixture of the two in any proportion.
[0185] Certain compounds of the invention may also exist in different stable conformational forms that can be separated. For example, torsional asymmetry due to limited rotation around an asymmetric single bond due to steric hindrance or ring strain may allow separation of different conformers. The invention includes each conformer of these compounds and mixtures thereof.
[0186] The term "pharmaceutically acceptable salt" as used herein refers to salts that are suitable for contact with human and lower animal tissues without excessive toxicity, irritation, allergic reactions, etc., and have a reasonable benefit / risk ratio within the scope of reasonable medical judgment. Pharmaceutically acceptable salts are well known in the art. For example, SM Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66: 2-19 (1977). These salts can be prepared in situ during the final separation and purification of the compounds of the present invention, or prepared separately by reacting the free base functional group with a suitable organic acid. Examples of pharmaceutically acceptable salts include, but are not limited to, non-toxic acid addition salts are amino salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid, or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include, but are not limited to, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentane-propionate, saccharate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxyethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, and the like. Representative alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, etc. Further pharmaceutically acceptable salts include non-toxic ammonium, quaternary ammonium and amine cations formed when appropriate using counterions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, alkyls having 1 to 6 carbon atoms, sulfonates and aryl sulfonates.
[0187] The term "pharmaceutically acceptable ester" as used herein refers to esters that hydrolyze in vivo, including those that readily decompose in the human body to leave the parent compound or a salt thereof. Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanoic acids, alkenoic acids, cycloalkanoic acids, and alkanedioic acids, wherein each alkyl or alkenyl moiety advantageously has no more than 6 carbon atoms. Examples of specific esters include, but are not limited to, formates, acetates, propionates, butyrates, acrylates, and ethylsuccinates.
[0188] Pharmaceutical composition
[0189] The pharmaceutical compositions of the present invention comprise a therapeutically effective amount of the compound of the present invention formulated together with one or more pharmaceutically acceptable carriers or excipients.
[0190] As used herein, the term "pharmaceutically acceptable carrier or excipient" refers to a non-toxic, inert solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. Some examples of materials that can be used as pharmaceutically acceptable carriers are sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose and cellulose acetate; tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; the composition may also contain ethanol and phosphate buffer solutions, and other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as colorants, release agents, coating agents, sweeteners, flavoring agents and fragrance enhancers, and preservatives and antioxidants may also be present in the composition according to the judgment of the formulator.
[0191] The pharmaceutical composition of the present invention can be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or by an implanted reservoir, preferably orally or by injection. The pharmaceutical composition of the present invention can contain any conventional non-toxic pharmaceutically acceptable carrier, adjuvant or carrier. In some cases, the pH value of the preparation can be adjusted with pharmaceutically acceptable acid, alkali or buffer to improve the stability of the preparation compound or its delivery form. The term parenteral injection used herein includes subcutaneous, intradermal, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.
[0192] Oral liquid dosage forms include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compound, the liquid dosage form may also contain inert diluents commonly used in the art, such as water or other solvents, solubilizers and emulsifiers, such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oil (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil and sesame oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol and sorbitan fatty acid esters, and mixtures thereof. In addition to inert diluents, oral compositions may also include adjuvants, such as wetting agents, emulsifiers and suspending agents, sweeteners, flavoring agents and flavor enhancers.
[0193] Injectable preparations, such as sterile injectable aqueous or oily suspensions, can be prepared using suitable dispersants or wetting agents and suspending agents according to known techniques. Sterile injectable preparations can also be sterile injectable solutions, suspensions or emulsions, dissolved in nontoxic parenteral acceptable diluents or solvents, for example, dissolved in 1,3-butanediol. Acceptable carriers and solvents that can be used include water, Ringer's solution, USP and isotonic sodium chloride solution. In addition, sterile fixed oils are generally used as solvents or suspending media. For this purpose, any mild fixed oil can be used, including synthetic monoglycerides or diglycerides. In addition, fatty acids such as oleic acid are used to prepare injections.
[0194] The injectable formulations can be sterilized, for example, by filtration through a bacteria-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
[0195] In order to prolong the effect of the drug, it is usually necessary to slow down the absorption of subcutaneous or intramuscular injection of the drug. This can be achieved by using a liquid suspension of crystalline or amorphous materials with poor water solubility. Then, the absorption rate of the drug depends on its dissolution rate, which in turn may depend on the crystal size and crystal form. Alternatively, delayed absorption of parenteral drug forms is achieved by dissolving or suspending the drug in an oily vehicle. Injectable depot forms are made by forming a microcapsule matrix of the drug in a biodegradable polymer (such as polylactic acid-polyglycolide). Depending on the ratio of the drug to the polymer and the properties of the specific polymer used, the drug release rate can be controlled. Examples of other biodegradable polymers include poly (orthoesters) and poly (anhydrides). Deposit injection preparations can also be prepared by embedding the drug in liposomes or microemulsions compatible with body tissues.
[0196] Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
[0197] Oral solid dosage forms include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier, such as sodium citrate or dicalcium phosphate and / or: a) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol and silicic acid, b) binders, such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia, c) humectants, such as glycerol, d) disintegrants, such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates and sodium carbonate, e) solution retarders, such as paraffin, f) absorption promoters, such as quaternary ammonium compounds, g) wetting agents, for example, cetyl alcohol and glyceryl monostearate, h) absorbents, such as kaolin and bentonite, i) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.
[0198] Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using excipients such as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
[0199] Solid dosage forms of tablets, dragees, capsules, pills and granules can be prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical preparation art. They may optionally contain opacifying agents and may be a composition that releases the active ingredient only or preferentially in a certain part of the intestinal tract, optionally in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.
[0200] The topical or transdermal dosage forms of the compounds of this invention include ointments, pastes, creams, emulsions, gels, powders, solutions, sprays, inhalants or patches. The active ingredient is mixed with a pharmaceutically acceptable carrier and any desired preservatives or buffers that may be needed under aseptic conditions. Ophthalmic preparations, ear drops, eye ointments, powders and solutions are also considered to be within the scope of the present invention.
[0201] Ointments, pastes, creams and gels may contain, in addition to the active compounds of this invention, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
[0202] In addition to the compounds of this invention, powders and sprays may contain excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicate and polyamide powder, or mixtures of these substances. Sprays may also contain common propellants such as chlorofluorocarbons.
[0203] Transdermal patches have the added advantage of providing controlled delivery of compounds into the body. This dosage form can be prepared by dissolving or dispensing the compound into an appropriate medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by providing a rate-controlling membrane or by dispersing the compound in a polymer matrix or gel.
[0204] For pulmonary administration, the therapeutic composition of the present invention is formulated in solid or liquid particle form and administered to the patient by direct administration (e.g., inhalation into the respiratory system). The solid or liquid particle form of the active compound prepared for the implementation of the present invention includes particles of respirable size: that is, particles of sufficiently small size that pass through the oral cavity and larynx during inhalation and enter the bronchi and alveoli. The delivery of aerosolized therapeutic agents, particularly aerosolized antibiotics, is known in the art (e.g., see U.S. Pat. No. 5,767,068 to VanDevanter et al., U.S. Pat. No. 5,508,269 to Smith et al., and WO 98 / 43650 to Montgomery, all of which are incorporated herein by reference).
[0205] Combination and Alternation Therapy
[0206] The compounds of the present invention can be used in combination with one or more antiviral therapeutic agents or anti-inflammatory agents useful in preventing or treating viral diseases or related pathophysiology. Therefore, the compounds of the present invention and their salts, solvates or other pharmaceutically acceptable derivatives can be used alone or in combination with other antiviral or anti-inflammatory therapeutic agents. The compounds herein and their pharmaceutically acceptable salts can be used in combination with one or more other agents that may be useful in preventing or treating respiratory diseases, inflammatory diseases, autoimmune diseases, etc., such as antihistamines, corticosteroids (e.g., fluticasone propionate, fluticasone furoate, beclomethasone dipropionate, budesonide, ciclesonide, mometasone furoate, triamcinolone, flunisolide), nonsteroidal anti-inflammatory drugs, leukotriene modifiers (e.g., montelukast, zafirlukast, pranlukast), tryptase inhibitors, IKK2 inhibitors, p38 inhibitors, Syk inhibitors, protease inhibitors such as elastase inhibitors, integrin antagonists (e.g., beta-2 integrin antagonists), adenosine A2a agonists, mediator release inhibitors such as sodium cromoglycate, 5-lipoxygenase inhibitors (zileuton), DP1 antagonists, DP2 antagonists, PI3Kδ inhibitors, ITK inhibitors, LP (lysophosphatidic acid) inhibitors or FLAP (5-lipoxygenase activating protein) inhibitors (e.g., 3-(3-(tert-butylthio)-1-(4-(6-ethyl)thiocarbazine)) inhibitors. oxypyridin-3-yl)benzyl)-5-((5-ethylpyridin-2-yl)methoxy)-1H-indol-2-yl)-2,2-dimethylpropionate sodium salt), bronchodilators (e.g., muscarinic antagonists, beta-2 agonists), methotrexate and similar agents; monoclonal antibody therapies such as anti-IgE, anti-TNF, anti-IL-5, anti-IL-6, anti-IL-12, anti-IL-1 and similar agents; cytokine receptor therapies such as etanercept and similar agents; antigen nonspecific immunotherapy (e.g., interferon or other Cytokines / chemokines, chemokine receptor modulators such as CCR3, CCR4 or CXCR2 antagonists, other cytokine / chemokine agonists or antagonists, TLR agonists and the like), suitable anti-infective agents include antibiotics, antifungals, anthelmintics, antimalarials, antiprotozoals, antituberculosis and antivirals, including those listed at https: / / www.drugs.Com / drug-Class / anti-infectives.html.
[0207] The compounds of the present invention and any other pharmaceutically active agents may be administered together or separately, and when administered separately, administration may occur simultaneously or sequentially in any order. The amounts of the compounds of the present invention and the other pharmaceutically active agents and the relative times of administration will be selected to achieve the desired combined therapeutic effect. The combined administration of the compounds of the present invention and their salts, solvates or other pharmaceutically acceptable derivatives with other therapeutic agents may be achieved by simultaneous administration in the following manners: (1) a single pharmaceutical composition comprising both compounds; or (2) separate pharmaceutical compositions comprising one compound each.
[0208] In certain embodiments of the combination therapy, the additional therapeutic agent is administered at a lower dose and / or frequency of administration than required to achieve similar results in treating or preventing a disease or condition mediated by 17β-HSD13.
[0209] While the invention has been described in terms of various preferred embodiments, it is not intended to be limited thereto, but those skilled in the art will recognize that changes and modifications can be made therein that are within the spirit of the invention and the scope of the appended claims.
[0210] Therapeutic activity
[0211] The effective therapeutic amount or dosage range of the compounds of the present invention may be from about 0.01 mg / Kg to about 500 mg / Kg, or from about 1 to about 50 mg / Kg. The effective therapeutic amount and dosage will also vary depending on the route of administration and the possibility of co-administration with other drugs.
[0212] According to the therapeutic methods of the present invention, a viral infection is treated or prevented in a patient, such as a human or another animal, by administering to the patient a therapeutically effective amount of a compound of the present invention, in such amounts and for such period of time as is necessary to achieve the desired result.
[0213] The "effective therapeutic amount" of the compounds of the present invention refers to the amount of the compound that produces a therapeutic effect on the subject at a reasonable benefit / risk ratio applicable to any medical treatment. The therapeutic effect can be objective (i.e., measurable by a test or marker) or subjective (i.e., the subject gives an indication of the effect or feels the effect). The effective amount of the above-mentioned compound can be in the range of about 0.1 mg / Kg to about 500 mg / Kg, preferably about 1 to about 50 mg / Kg. The effective dose will also vary depending on the route of administration and the possibility of co-administration with other drugs. However, it should be understood that the total daily dosage of the compounds and compositions of the present invention will be determined by the attending physician within the scope of reasonable medical judgment. The specific therapeutically effective dose level for any particular patient will depend on various factors, including the disease being treated and the severity of the disease; the activity of the specific compound used; the specific ingredients used; the patient's age, weight, general health, sex and diet; the administration time, route of administration and excretion rate of the specific compound used; the duration of treatment; drugs used in combination or simultaneously with the specific compound used; and similar factors well known in the medical field.
[0214] The total daily dose of the compounds of this invention administered to humans or other animals in single or divided doses can be, for example, 0.01 to 50 mg / kg body weight, or more generally 0.1 to 25 mg / kg body weight. Single-dose compositions can include such an amount or its multiple to constitute a daily dose. In general, treatment regimens according to the present invention include administering about 10 mg to about 1000 mg of the compounds of this invention to patients who need such treatment in single or multiple doses every day.
[0215] The compounds of the invention described herein can be administered, for example, by injection, intravenous, intraarterial, subcutaneous, intraperitoneal, intramuscular or subcutaneous administration; or orally, buccal, nasal, transmucosal, topical, ophthalmic preparations or inhalation, in a dosage range of about 0.1 to about 500 mg / kg body weight, or 1 mg to 1000 mg / dose taken every 4 to 120 hours, or as required by a particular drug. The methods herein contemplate the administration of an effective amount of a compound or compound composition to achieve the desired or described effect. Typically, the pharmaceutical compositions of the present invention will be administered about 1 to about 6 times a day, or as a continuous infusion. Such administration can be used as a chronic or acute treatment. The amount of active ingredient that can be combined with a pharmaceutical excipient or carrier to produce a single dosage form will vary depending on the host being treated and the specific mode of administration. A typical preparation will contain about 5% to about 95% of the active compound (w / w). Alternatively, such preparations may contain about 20% to about 80% of the active compound.
[0216] Lower or higher doses than those recited above may be required. The specific dosage and treatment regimen for any particular patient will depend on a variety of factors, including the activity of the specific compound used, age, weight, general health, sex, diet, time of administration, rate of excretion, drug combination, severity and course of the disease, condition or symptoms, the patient's disposition to the disease, condition or symptoms, and the judgment of the attending physician.
[0217] After the patient's condition improves, if necessary, a maintenance dose of the compounds, compositions or combinations of the present invention may be administered. Subsequently, depending on the symptoms, the dosage or frequency of administration or both may be reduced to a level at which the condition improves when the symptoms are relieved to the desired level. However, if disease symptoms recur, the patient may require long-term intermittent treatment.
[0218] When the compositions of the present invention comprise a combination of a compound of formula (I) as described herein and one or more additional therapeutic or preventive agents, the dosage levels of the compounds and additional agents should be about 1 to 100%, more preferably about 5 to 95%, of the dosage normally administered in a monotherapy regimen. As part of a multiple dose regimen, the additional agents may be administered separately from the compounds of the present invention. Alternatively, these agents may be part of a single dosage form, mixed with the compounds of the present invention in a single composition.
[0219] "Additional therapeutic or preventive agents" include, but are not limited to, immunotherapy (such as interferon), therapeutic vaccines, antifibrotic agents, anti-inflammatory agents (such as corticosteroids or nonsteroidal anti-inflammatory drugs), bronchodilators (such as β2 adrenergic agonists and xanthines (such as theophylline)), mucolytics, antimuscarinics, antileukotrienes, cell adhesion inhibitors (such as ICAM-1 antagonists), antioxidants (such as N-acetylcysteine), cytokine agonists, cytokine antagonists, lung surfactants and / or antibacterial and antiviral agents (such as ribavirin and amantidine). The compositions of the present invention can also be used in combination with gene replacement therapy.
[0220] abbreviation
[0221] The following abbreviations are used in the protocol description and subsequent examples:
[0222] Alloc represents allyloxycarbonyl;
[0223] Alloc-Cl represents allyl chloroformate;
[0224] ASK1 stands for apoptosis signal-regulating kinase 1;
[0225] ATP stands for adenosine triphosphate;
[0226] Boc represents tert-butyloxycarbonyl;
[0227] BOP-Cl stands for bis(2-oxo-3-oxazolinyl)phosphoryl chloride;
[0228] Cbz represents benzyloxycarbonyl;
[0229] Cbz-Cl represents benzyl chloroformate;
[0230] CDI stands for carbodiimide;
[0231] (COCl) 2 stands for oxalyl chloride;
[0232] DBU stands for 1,8-diazabicyclo[5.4.0]undec-7-ene;
[0233] DCC stands for N,N'-dicyclohexylcarbodiimide;
[0234] 1,2-DCE stands for 1,2-dichloroethane;
[0235] DCM stands for dichloromethane;
[0236] DIPEA or Hunig's group or i-Pr2NEt represents N,N-diisopropylethylamine;
[0237] DMAc stands for N,N-dimethylacetamide;
[0238] DMAP stands for N,N-dimethylaminopyridine;
[0239] DMF stands for N,N-dimethylformamide;
[0240] EDC stands for 1-(3-diethylaminopropyl)-3-ethylcarbodiimide hydrochloride;
[0241] EGTA stands for ethylene glycol bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid;
[0242] ESI stands for electrospray ionization;
[0243] Et 3 N or TEA represents triethylamine;
[0244] Et 2 O represents diethyl ether;
[0245] EtOAc stands for ethyl acetate;
[0246] Ghosez's reagent stands for 1-chloro-N,N,2-trimethyl-1-propenamine;
[0247] HATU stands for 1-[(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridine-3-oxide hexafluorophosphate;
[0248] HEPES stands for 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid);
[0249] IC 50 represents half-maximal inhibitory concentration;
[0250] KOt-Bu stands for potassium tert-butoxide;
[0251] LCMS stands for liquid chromatography-mass spectrometry;
[0252] MeCN stands for acetonitrile;
[0253] MTBE stands for methyl tert-butyl ether;
[0254] m / z represents mass-to-charge ratio;
[0255] NaOt-Bu represents sodium tert-butoxide;
[0256] NMP stands for N-methyl-2-pyrrolidone;
[0257] NMR stands for nuclear magnetic resonance spectroscopy;
[0258] -OMs or mesylate stands for mesylate;
[0259] -OTf or triflate represents trifluoromethanesulfonate;
[0260] -OTs or p-toluenesulfonate represents p-toluenesulfonate;
[0261] Pd 2 (dba) 3 stands for tris(diphenylacetophenone)dipalladium(0);
[0262] P(o-Tolyl) 3 stands for tri(o-tolyl)phosphine;
[0263] PyAOP stands for 7-azabenzotriazole-1-oxy)tripyrrolylphosphonium hexafluorophosphate;
[0264] PyBOP stands for benzotriazole-1-oxytripyrrolephosphonium hexafluorophosphate;
[0265] STK3 stands for serine / threonine-protein kinase 3;
[0266] TEA stands for triethylamine;
[0267] THF stands for tetrahydrofuran.
[0268] Synthesis method
[0269] All references cited herein, whether in printed, electronic, computer-readable storage medium or other form, are expressly incorporated herein by reference in their entirety, including but not limited to abstracts, articles, journals, publications, texts, treatises, Internet websites, databases, patents and patent publications.
[0270] Various changes and modifications to the disclosed embodiments will be apparent to those skilled in the art and may be made without departing from the spirit of the invention and the scope of the appended claims, including but not limited to changes and modifications relating to the chemical structures, substituents, derivatives, formulations and / or methods of the invention.
[0271] While the invention has been described in terms of various preferred embodiments, it is not intended to be limited thereto, but those skilled in the art will recognize that variations and modifications can be made within the spirit of the invention and scope of the appended claims.
[0272] The compounds and methods of the present invention will be better understood in conjunction with the following synthetic schemes, which illustrate methods for preparing the compounds of the present invention. These schemes are intended to be illustrative only and are not intended to limit the scope of the present invention.
[0273] As shown in Scheme 1, in a one-pot process, the compound of formula (I) can be prepared from an aminoester compound (1) and an amide compound (2) prepared according to the literature (New inhibitors of 17b-hydroxysteroid dehydrogenase type 1, Molecular and Cellular Endocrinology 2006, 248, 192-198, Josef Messinger, Leena Hirvela, Pasi Koskimies, Bettina Husen, Lauri Kangas, Olli Pentikainen, Pauli Saarenketo and Hubert Thole) in POCl 3 , SOCl 2 or PCl 5 Prepared by condensation reaction in the presence of 1 , R 2 , R 3 , R 4 , R 5 , R 6 and M are as described above. Therefore, a mixture of the aminoester compound (1) and the amide compound (2) in an aprotic solvent is treated with POCl 3 , SOCl 2 or PCl 5The aprotic solvent may be, for example but not limited to, THF, DCE and DMF. The reaction temperature is 0°C to 140°C.
[0274] Solution 1
[0275]
[0276] Alternatively, as shown in Scheme 2, compounds of formula (I) can also be prepared in a stepwise manner, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and M are as described above. Amide compound (2) can be reacted with POCl in an aprotic solvent such as DCM, DCE, THF or DMF. 3 , SOCl 2 or PCl 5 The reaction is carried out at 0°C to 80°C to form chlorinated imine (3), which then reacts with aminoester compound (1) to obtain cyclized compound (I). The reaction temperature is 0°C to 140°C.
[0277] Solution 2
[0278]
[0279] Alternatively, as shown in Scheme 3, the compound of formula (I) can also be prepared by a coupling reaction between a chloropyrimidone compound (7) and an organometallic reagent such as a boronic acid or a related boron reagent partner (8) catalyzed by a transition metal / phosphine ligand complex, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6and M are as described above. The catalyst used in the reaction may be, but is not limited to, bis(triphenylphosphine)palladium(II) chloride. The base used in the reaction may be, but is not limited to, cesium carbonate. In the presence of a suitable coupling agent and an organic base, the compound (1) in an aprotic solvent is first treated with an amine compound (4) to obtain a urea compound (5). A suitable coupling reagent may be, for example, but not limited to, CDI, triphosgene or ethyl chloroformate, and an organic base may be, for example, but not limited to, DBU, DIPEA or TEA. An aprotic solvent may be, for example, but not limited to, MecN, THF, DCE or DMF. The reaction temperature is 0°C to 80°C. The urea compound (5) is then treated with a suitable inorganic base at high temperature in an alcohol solvent to provide a pyrimidinedione compound (6). The inorganic base may be, for example, but not limited to, NaOMe, NaOEt or NaOtBu. The alcohol solvent may be, for example, but not limited to, MeOH, EtOH or tBuOH. The temperature is 40°C to 80°C. The chloropyrimidone compound (7) is prepared from the pyrimidinedione compound (6) in the presence of a suitable chlorinating agent in an aprotic solvent at high temperature. A suitable chlorinating agent may be, for example, but not limited to, POCl 3 The aprotic solvent may be, for example, but not limited to DCE. The reaction temperature is 80°C to 140°C. The chloropyrimidone compound (7) reacts with a boric acid complex or a related boron reagent (8) in a mixed solvent mixture under the catalysis of a transition metal / phosphine ligand complex. The solvent in the coupling reaction may be, but not limited to, DME / H 2 O, dioxane / H 2 O, toluene / H 2 O, etc. The reaction temperature is 0°C to 140°C.
[0280] Solution 3
[0281]
[0282] As shown in Scheme 4, the compound of formula (IV) can be prepared by reacting compound (9) and R 9 -LG is synthesized by substitution reaction in the presence of aprotic solvent and base, where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and M are as described above. The base can be an organic base or an inorganic base, but is not limited to pyridine, DIPEA, DMAP, Cs 2 CO 3 , NaH, etc. The aprotic solvent can be pyridine, MecN, THF, DCE or DMF. The reaction temperature is 0°C to 80°C.
[0283] Solution 4
[0284] Example
[0285] The compounds and methods of the present invention will be better understood in conjunction with the following examples, which are intended to illustrate but not to limit the scope of the present invention. The starting materials can either be obtained from commercial suppliers or prepared by methods well known to those skilled in the art.
[0286] Synthesis of 2-(2-cyclopropyl-4-methoxyphenyl)-3-(oxazol-5-ylmethyl)-4-oxo-3,4-dihydrobenzo[4,5]thieno[2,3-d]pyrimidin-8-yl acetate (Example 1).
[0287] Example 1
[0288]
[0289] Step 1
[0290]
[0291] Under nitrogen atmosphere, compound 1-2 (5.0 g, 20.4 mmol), cyclopropylboronic acid (5.3 g, 61.2 mmol), tetrakis(triphenylphosphine)palladium (2.4 g, 2.0 mmol), potassium carbonate (8.5 g, 61.2 mmol) were added to a 250 mL round-bottom flask, followed by dioxane (82 mL) and water (20 mL). The suspension was heated at 100 ° C for 48 hours. Cooled to room temperature, diluted with ethyl acetate, washed with water and brine, respectively. Dry with sodium sulfate, filter, concentrate, and purify by CombiFlash (120 grams of silica, ethyl acetate / n-hexane: 0-20%) to obtain compound 1-3 as a colorless liquid 2.4 g, yield 57.0%. LC-MS observed [M+H] to be 207.10. 1 H NMR (400 MHz, CHLOROFORM-d) δ 7.86 (d, J = 8.7 Hz, 1H), 6.70 (dd, J = 8.7, 2.6 Hz, 1H), 6.51 (d, J = 2.6 Hz, 1H), 3.88 (s, 3H), 3.82 (s, 3H), 2.90-2.69 (m, 1H), 1.11-0.90 (m, 2H), 0.77-0.60 (m, 2H).
[0292] Step 2
[0293]
[0294] Methanol (87 mL), water (29 mL) and sodium hydroxide (2.3 g, 58.2 mmol) were added to a 250 mL round-bottom flask containing compound 1-3 (2.4 g, 11.6 mmol), and the mixture was stirred at 60 ° C overnight. The reaction was determined to be complete by TLC (70% ethyl acetate / n-hexane). Cool to room temperature and concentrate to remove half of the solvent. 10 mL of water was added and the white suspension was cooled to 0 ° C. 3N hydrochloric acid (23.3 mL, 69.8 mmol) was added dropwise to acidify to a pH of about 1. The precipitate was filtered through a Buchner funnel and dried under vacuum to obtain compound 1-4 as a white powder, 2.17 g, with a yield of 97%. LC-MS observed [M+H] to be 193.0. 1 HNMR (400 MHz, DMSO-d 6 ) δ12.52 (s, 1H), 7.77 (d, J = 8.7Hz, 1H), 6.78 (dd, J = 8.7, 2.6Hz, 1H), 6.43 (d, J = 2 .6Hz, 1H), 3.78 (s, 3H), 3.00-2.79 (m, 1H), 1.06-0.85 (m, 2H), 0.80-0.59 (m, 2H).
[0295] Step 3
[0296]
[0297] 1-4 (0.45 g, 2.34 mmol), 1-5 (0.32 g, 2.34 mmol), HATU (1.42 g, 3.75 mmol), CH 2 Cl 2 (7.5 mL) and DIPEA (1.31 mL, 7.49 mmol), the resulting mixture was stirred at room temperature for 25 hours. Diluted with dichloromethane, washed with saturated sodium bicarbonate and brine. Dry over sodium sulfate, filtered, concentrated, and passed through a CombiFlash (24 g SiO 2 , ethyl acetate / n-hexane: 0-100%) to obtain compound 1-6 as a white solid, 0.41 g, yield 63.8%. LC-MS observed [M+H] was 273.12. 1H NMR (400MHz, chloroform-d) δ7.86 (s, 1H), 7.46 (d, J=8.5Hz, 1H), 7.06 (s, 1H), 6.71 (dd, J=8.7, 2.5Hz, 1H), 6.49 (d, J=2 .5Hz, 1H), 6.45 (s, 1H), 4.71 (d, J=5.7Hz, 2H), 3.79 (s, 3H), 2.25 (m, 1H), 1.11-0.85 (m, 2H), 0.85-0.62 (m, 2H).
[0298] Step 4
[0299]
[0300] Compound 1-7 (0.52 g, 2.203 mmol), compound 1-6 (0.30 mg, 1.102 mmol), DCE (6.12 mL) and phosphorus oxychloride (154 μL, 1.65 mmol) prepared according to the literature method (Molecular and Cellular Endocrinology 2006, 248, 192-198) were added to a 25 mL round-bottom flask, and the suspension was stirred at 80 ° C for 18 hours. Dilute with dichloromethane and collect the insoluble brown solid with a Buchner funnel. The filtrate was washed with saturated NaHCO 3 The organic layer was dried over sodium sulfate, filtered, concentrated, and flashed through a CombiFlash (40 g SiO 2 , ethyl acetate / cyclohexane: 0-100%) to obtain compound 1-8 as a light yellow solid, 0.14 g, yield 28.5%. LC-MS observed [M+H] was 446.12. 1 H NMR (400 MHz, DMSO-d 6 )δ10.68 (s, 1H), 8.22 (s, 1H), 8.02 (dd, J=7.9, 0.9Hz, 1H), 7.43 (t, J=7.9Hz, 1H), 7.37 (d, J=8.5Hz, 1H), 6.98 (dd, J=7.9, 1.0Hz, 1H), 6.88 (dd, J=8.5, 2.5Hz, 1H), 6.85 (s, 1H) , 6.48 (d, J=2.5Hz, 1H), 5.40 (d, J=15.9Hz, 1H), 5.09 (dd, J=15.9, 1.1Hz, 1H), 3.82 (s, 3H), 1.57 (m, J=8.0, 7.5, 4.5Hz, 1H), 0.83 (m, J=7.8, 4.7Hz, 3H), 0.63 (m, J=4.2Hz, 1H).
[0301] Step 5
[0302]
[0303] Compound 1-8 (0.1 g, 0.22 mmol) and acetic anhydride (106 μl, 1.12 mmol) were added to a 2-dram vial and the reaction was stirred at room temperature for 16 hours. Diluted with dichloromethane and washed with saturated sodium bicarbonate. Drying with sodium sulfate, filtering, concentrating, and passing through CombiFlash (12 g SiO 2 , ethyl acetate / n-hexane: 0-100%) to obtain compound 1 as a white foam, 0.1 g, yield 91%. LC-MS observed [M+H] was 488.13. 1 H NMR (400 MHz, chloroform-d) δ 8.56 (dd, J = 7.9, 1.0 Hz, 1H), 7.74 (s, 1H), 7.57 (t, J = 8.0 Hz, 1H), 7.31 (dd, J = 8.0, 1.0 Hz, 1H), 7.27 (s, 0H), 7.24 (d, J = 8.4 Hz, 1H), 6.89-6.78 ( m, 2H), 6.49 (d, J=2.5Hz, 1H), 5.61 (d, J=15.4Hz, 1H), 5.09 (dd, J=15.3, 0.8Hz, 1 H), 3.85 (s, 3H), 2.42 (s, 3H), 1.56 (m, 1H), 1.01-0.76 (m, 3H), 0.74-0.56 (m, 1H).
[0304] Synthesis of 2-(2-cyclopropyl-4-methoxyphenyl)-3-(oxazol-5-ylmethyl)-4-oxo-3,4-dihydrobenzo[4,5]thieno[2,3-d]pyrimidin-8-ylpropanoate (Example 2).
[0305] Example 2
[0306]
[0307] Example 2 was prepared following a procedure similar to that described for compound 1. LC-MS observed [M+H] 502.14. 1H NMR (400 MHz, chloroform-d) δ 8.55 (dd, J = 8.0, 1.0 Hz, 1H), 7.75 (s, 1H), 7.57 (t, J = 8.0 Hz, 1H), 7.32 (dd, J = 8.0, 1.0 Hz, 1H), 7.24 (d, J = 8.5 Hz, 1H), 6.88-6.79 (m, 2H), 6.49 (d, J = 8.5 Hz, 1H). =2.5Hz, 1H), 5.69-5.49 (m, 1H), 5.09 (dd, J = 15.4, 0.9Hz, 1H), 3.85 (s, 3H), 2.72 (q , J=7.5Hz, 2H), 1.56 (m, 1H), 1.34 (t, J=7.5Hz, 3H), 0.97-0.76 (m, 3H), 0.66 (m, 1H).
[0308] Synthesis of 2-(2-cyclopropyl-4-methoxyphenyl)-3-(oxazol-5-ylmethyl)-4-oxo-3,4-dihydrobenzo[4,5]thieno[2,3-d]pyrimidin-8-ylbenzoate (Example 3)
[0309] Example 3
[0310]
[0311]
[0312] Example 3 was prepared following a procedure similar to that described for Compound 1.
[0313] LC-MS observed [M+H]: 282.08. 1 H NMR (400 MHz, DMSO-d 6 )δ8.05 (s, 2H), 7.69 (d, J = 8.1Hz, 1H), 7.26 (t, J = 8.0Hz, 1H), 6.88 (d, J = 8.1Hz , 1H), 5.37 (s, 2H), 4.36 (q, J=7.0Hz, 2H), 3.47 (s, 3H), 1.41 (t, J=7.1Hz, 3H).
[0314] The following examples were prepared by procedures similar to those described above. Compounds 17-24 were isolated as trifluoroacetate salts.
[0315]
[0316]
[0317]
[0318]
[0319]
[0320]
[0321]
[0322]
[0323]
[0324]
[0325]
[0326]
[0327]
[0328]
[0329]
[0330]
[0331]
[0332]
[0333]
[0334]
[0335]
[0336]
[0337]
[0338]
[0339]
[0340]
[0341]
[0342]
[0343] analyze
[0344] 17β-HSD13 Rapid flame mass spectrometry (RF / MS analysis) . Recombinant human 17β-HSD13 was expressed and purified from sf9 cells at Charles River Labs (SffonWalden, UK). Leukotriene B4 (Catalog No. 71160-24-2) and 12-oxoleukotriene B4 (Catalog No. 20140) were purchased from Cayman Chemicals (Ann Arbor, MI). NAD+ (Catalog No. N8285), BSA (Catalog No. A7030), DMSO (Catalog No. D2650), and Tween-20 (Catalog No. 11332465001) were purchased from Sigma (St. Louis, MO). Formic acid (Catalog No. 28905) was from Thermo Fisher Scientific, and 384 deep well PP microplates (Catalog No. 784261) were from Greiner Bio-One. Typical IC performed in 384w PP microplates 50 In the assay, test compounds (0-100 μM) were incubated with HSD17B13 (80 nM), LTB4 (10 μM) and NAD+ (0.5 mM) in 10 μL assay buffer (20 mM Tris (pH 7.5), BSA (0.005%) and Tween-20 (0.01%) at room temperature for 3 hours. The assay was terminated by adding 20 μL of 0.15% aqueous formic acid and the plate was frozen at -80°C. RF / MS analysis was performed on a RapidFire RF300 system (Agilent Technologies, Inc.) from PureHoney Technologies (Billerica, MA) coupled to an API 4000 triple quadrupole mass spectrometer (SCiex) equipped with an Agilent RapidFire A-type cartridge (C4). The mobile phases were 0.09% formic acid and 0.01% trifluoroacetic acid in water (buffer A) and 0.09% formic acid and 0.01% trifluoroacetic acid in 80% acetonitrile in water (buffer B). The fast flame analysis method conditions were as follows: 250 ms uptake, 3000 ms loading / desalting, 4000 ms elution, 500 ms re-equilibration. RF-MS / MS was performed at negative polarity (-4500 V), source temperature was 650°C, and gas 1 and gas 2 of nitrogen were set to 50. The curtain gas and collision gas were also nitrogen and were set to 20 and 12, respectively. The SRM transitions for leukotriene B4 (335.3) and 12-oxoleukotriene B4 (333.3) were optimized using Discovery Quant software, and the extracted ion counts for these analytes were determined.
[0345] Data Analysis. 17β-HSD13 enzyme activity was measured as percent conversion of extracted ion counts and normalized to high and low controls to determine the percent activity remaining at various concentrations of test compound. Data were fitted to normalized activity (variable slope) versus concentration in GraphPad Prism 7 to determine the IC 50 All experiments were performed in duplicate.
[0346] The inhibitory effect of the compounds of formula (I) on 17β-HSD13 was evaluated using the above method. 50 The ranges are as follows: A is <0.1 μM; B is 0.1 μM-1.0 μM; C is 1.0 μM-10 μM; D is >10 μM.
[0347]
[0348]
[0349] While the invention has been particularly shown and described with reference to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made without departing from the scope of the invention as encompassed by the appended claims.
Claims
1. A compound represented by formula I or a pharmaceutically acceptable salt or ester thereof: wherein: M is S, SO, SO2, O or NR7; R1 and R2 are each independently selected from: 1) Hydrogen; 2) optionally substituted C1-C8 alkyl; 3) optionally substituted C2-C8 alkenyl; 4) optionally substituted C2-C8 alkynyl; 5) optionally substituted C3-C8 cycloalkyl; 6) optionally substituted aryl; 7) optionally substituted arylalkyl; 8) optionally substituted 3 to 8 membered heterocycloalkyl; 9) optionally substituted heteroaryl; and 10) optionally substituted heteroarylalkyl; R3, R4, R5 and R6 are each independently selected from hydrogen, halogen, -CN, -OR9, -SR9, -C(O)R7, -C(O)OR7, -NR7R8, -C(O)NR7R8, optionally substituted C1-C8 alkyl, optionally substituted aryl and optionally substituted heteroaryl; Alternatively, R5 and R6 together with the carbon atoms to which they are attached form an optionally substituted carbocyclic or heterocyclic ring; Alternatively, R4 and R5 together with the carbon atoms to which they are attached form an optionally substituted carbocyclic or heterocyclic ring; Alternatively, R3 and R4 together with the carbon atoms to which they are attached form an optionally substituted carbocyclic or heterocyclic ring; Each R7 and R8 is independently selected from: 1) Hydrogen; 2) optionally substituted C1-C8 alkyl; 3) optionally substituted C2-C8 alkenyl; 4) optionally substituted C2-C8 alkynyl; 5) optionally substituted C3-C8 cycloalkyl; 6) optionally substituted 3 to 8 membered heterocycloalkyl; 7) optionally substituted aryl; 8) optionally substituted arylalkyl; 9) optionally substituted heteroaryl; and 10) optionally substituted heteroarylalkyl; Alternatively, R7 and R8 together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring; R9 is selected from: 1) Hydrogen; 2) optionally substituted C1-C8 alkyl; 3) optionally substituted C2-C8 alkenyl; 4) optionally substituted C2-C8 alkynyl; 5) optionally substituted C3-C8 cycloalkyl; 6) optionally substituted 3 to 8 membered heterocycloalkyl; 7) optionally substituted aryl; 8) optionally substituted arylalkyl; 9) optionally substituted heteroaryl; 10) optionally substituted heteroarylalkyl; 11)-C(O)R 11 ; 12)-C(O)NR 11 R 12 ; 13)-C(O)OR 11 ; 14)-P(O)(OR 13 )2; and 15)-P(O)(OR 13 )(NR 11 R 12 ); Each R 11 and R 12 Independently selected from: 1) Hydrogen; 2) optionally substituted C1-C8 alkyl; 3) optionally substituted C2-C8 alkenyl; 4) optionally substituted C2-C8 alkynyl; 5) optionally substituted C3-C8 cycloalkyl; 6) optionally substituted 3 to 8 membered heterocycloalkyl; 7) optionally substituted aryl; 8) optionally substituted arylalkyl; 9) optionally substituted heteroaryl; and 10) optionally substituted heteroarylalkyl; And R 13 is hydrogen, optionally substituted C1-C8 alkyl or Na+.
2. The compound according to claim 1, wherein M is S or NR7, and R7 is as defined in claim 1.
3. The compound according to claim 1, wherein R1 is selected from the following groups, each of which is optionally substituted: R2 is selected from the following groups, each of which is optionally substituted:
4. The compound according to claim 1, which is represented by formula (IV) or formula (V), or a pharmaceutically acceptable salt thereof: wherein R1, R2, R3, R4, R5, R9 and R7 are as defined in claim 1.
5. The compound according to claim 4, wherein R9 is selected from the following groups, each of which is optionally substituted:
6. The compound according to claim 1, which is represented by formula (X) or formula (XI), or a pharmaceutically acceptable salt thereof: in, R1, R2, R7 and R9 are as defined in claim 1.
7. The compound according to claim 1, selected from the compounds represented by formula (X) or pharmaceutically acceptable salts thereof, wherein R9 is hydrogen, and R1 and R2 are described for each compound in the following table:
8. The compound according to claim 1, selected from the compounds represented by formula (X) or pharmaceutically acceptable salts thereof, Wherein R1, R2 and R9 are described for each compound in the following table:
9. The compound according to claim 1, selected from the following compounds or pharmaceutically acceptable salts thereof:
10. A pharmaceutical composition comprising the compound according to any one of claims 1 to 9 and a pharmaceutically acceptable carrier or excipient.
11. A method for preventing or treating a disease or condition mediated by 17β-HSD13 in a subject in need thereof, comprising administering to the subject an effective therapeutic amount of a compound according to any one of claims 1 to 9.
12. The method of claim 11, wherein the disease or condition mediated by 17β-HSD13 is selected from non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), cirrhosis, liver fibrosis and hepatocellular carcinoma (HCC).
13. Use of the compound of any one of claims 1 to 9 in the preparation of a medicament for treating or preventing a disease or condition mediated by 17β-HSD13.
14. The use according to claim 13, wherein the disease or condition mediated by 17β-HSD13 is selected from non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), cirrhosis, liver fibrosis and hepatocellular carcinoma (HCC).
Citation Information
Patent Citations
Inhibition Of HSD17B13 In The Treatment Of Liver Disease In Patients Expressing The PNPLA3 I148M Variation
US20190106749A1
Aminoglycoside formulation for aerosolization
US5508269A
Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
US5767068A
A method and a tobramycin aerosol formulation for treatment, prevention and containment of tuberculosis
WO1998043650A1
HSD17b13 variants and uses thereof
WO2018136758A1
